Beneath the individual findings, a single pattern is forming. The psychedelic ecosystem is entering its first genuine scientific reckoning — not a political one, not a media cycle, but a methodological one. The fluoxetine washout question, the cardiac safety question, and the endpoint validity question are all expressions of the same deeper current: first-generation trial design is meeting second-generation data, and the fit is imperfect. This is not a crisis — it is maturation. The highest trajectory available from this moment is not acceleration but precision: trials that survive this scrutiny will produce the kind of evidence that earns durable regulatory trust rather than provisional approval. The bifurcation between raw ibogaine and oxa-noribogaine analogs — already forming in preclinical pipelines — is the market's early signal that the ecosystem is beginning to self-select for rigor. That selection, however uncomfortable in the short term for companies carrying legacy trial architectures, is the mechanism by which the field earns the next decade.
The people inside today's signals are veterans sitting in clinical waiting rooms, addiction survivors whose trial enrollment may now be paused for endpoint renegotiation, and the clinicians who promised them something real. For a veteran who has already survived the gauntlet of PTSD only to find ibogaine access gated by cardiac screening requirements they may not be able to meet, the bifurcation between raw ibogaine and clean analogs is not an abstraction — it is a timeline, measured in years, measured in nights. What the highest positive outcome means for them specifically is this: that the methodological reckoning happening now produces trials rigorous enough to reach approval, rather than trials that move fast and collapse at the NDA stage. Slower and right is the only path that actually reaches them. The science being demanded of ibogaine today is the science that eventually protects the veteran who needs it most — not from the molecule, but from a regulatory rejection that forecloses access entirely.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
What is being called in cannot be called back.
62%
FDA requires heart screening tests for ibogaine drug trials
The FDA (the US drug regulator) will publish official rules saying anyone testing ibogaine in humans must do EKG heart tests first and check for dangerous heart rhythms. This matters because ibogaine can affect your heart, and regulators need to protect trial volunteers—but the new rules won't stop companies from developing safer versions of ibogaine.
→ The FDA will probably require heart tests before any ibogaine human trial by mid-2026, which protects patients but doesn't block the drug from development.
Resolves: 2026-09-30 · USA
REGULATION
the precise call ▾
FDA will issue formal guidance requiring mandatory cardiac screening protocols (ECG, QTc thresholds) for any ibogaine IND by Q3 2026, effectively gatekeeping clinical access without blocking analog development.. Multiple ibogaine cardiac safety papers constitute a regulatory forcing function FDA cannot ignore without institutional liability. Formal guidance is the minimally invasive, institutionally predictable response. However, FDA guidance timelines routinely slip; Q3 2026 is aggressive given FDA's curre
52%
Two major psilocybin trials will require patients to stop antidepressants
Researchers running big psilocybin studies will update their rules to require people taking fluoxetine (Prozac) to stop the drug before the trial, and they'll document this in public trial databases. This matters because fluoxetine might interfere with psilocybin's effects, and trials need to show clean results.
→ Two psilocybin trials will probably require patients to stop Prozac before treatment, and announce it publicly by end of 2026.
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
At least two Phase 3 psychedelic trials will formally adopt standardized fluoxetine washout protocols (documented in trial registry or protocol amendment) by Q4 2026.. The fluoxetine-behavior interaction finding creates proactive protocol amendment incentive at MAPS-affiliated and FDA-scrutinized sites. However, 'formally adopt' requires verifiable protocol amendment or registry update, not just internal policy. The base rate for mid-trial protocol amendments at t
38%
FDA may halt a psilocybin trial over treatment endpoint mismatch
The FDA (US drug regulator) might put a clinical hold on or ask researchers to redesign at least one big psilocybin or ibogaine addiction trial because the main goal (stopping relapse) doesn't match how the drug actually works (helping people forget trauma). This matters because if the FDA thinks a trial is measuring the wrong thing, it can freeze the study until researchers fix it.
→ The FDA might shut down or demand major changes to one psilocybin addiction trial by Q2 2027 if the way it measures success doesn't match how the drug actually works.
Resolves: 2027-06-30 · USA
RESEARCH
the precise call ▾
FDA will formally request endpoint renegotiation or place a clinical hold on at least one active psilocybin or ibogaine addiction trial citing mismatch between extinction-enhancement mechanism and relapse-prevention primary endpoint by Q2 2027.. If the psilocybin-ibogaine extinction-without-relapse-prevention finding is robust and published in a high-impact venue, FDA's Division of Psychiatry has grounds to question endpoint validity. However, FDA clinical holds and formal endpoint renegotiations are rare and require substantial evidentiary
28%
Psilocybin trials will require antidepressant washout by July 2026
At least two major psilocybin studies will update their trial rules to require fluoxetine washout and publish this change publicly by July 30, 2026. This is a tighter deadline than the previous prediction and matters because protocol changes usually take months to approve through review boards.
→ It's unlikely that two trials will formally announce Prozac-washout rules by July 2026—that's only three months away and these processes are slow.
Resolves: 2026-07-30 · USA
RESEARCH
the precise call ▾
Fluoxetine washout standardization will be documented as adopted protocol practice across at least two Phase 3 psychedelic trials by 2026-07-30.. This is largely a duplicate of the Q4 2026 washout prediction above but with a more aggressive resolve date of 2026-07-30, only three months away. Formal protocol amendments take time to negotiate with IRBs and FDA. The July 2026 deadline is very tight; base rate for two independent trial protocol a
48%
Safer ibogaine versions will be worth much more than original
Companies developing oxa-noribogaine (a safer chemical cousin of ibogaine) will be valued at least 40% higher than companies focusing only on raw ibogaine, within one year of May 2026. This matters to investors because it signals which version of the drug the market thinks will actually work and get approved.
→ Safer ibogaine versions might be worth 40% more than regular ibogaine by mid-2027, but this is uncertain in an illiquid, chaotic market.
Resolves: 2027-05-01 · Global
MARKET
the precise call ▾
Oxa-noribogaine developers will achieve a sustained public market or disclosed private valuation premium of 40%+ over comparable raw ibogaine-focused companies within 12 months of 2026-05-01.. The cardiac safety bifurcation thesis is directionally sound but the 40% premium threshold is highly specific and hard to measure cleanly given illiquid private markets and small public floats. Comparator selection is contested. Even if the bifurcation is real, noisy markets and idiosyncratic compan